Can Adma Biologics Climb 25.5 percent to Reach the Level Wall Street Analysts Expect?
| ADMA Stock | USD 15.83 0.56 3.42% |
About 61% of ADMA Biologics' investor base is looking to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are alarmed. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
The mean of analysts price targets for Adma Biologics points to a 25.5 percent upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read at zacks.com
 |
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
ADMA Biologics is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
| IBIO | Ibio | 9.95 | ||||
| XFOR | X4 Pharmaceuticals | 8.11 | ||||
| ATRA | Atara Biotherapeutics | 1.30 | ||||
| CRBU | Caribou Biosciences | 0.86 | ||||
| BCRX | BioCryst Pharmaceuticals | 0.81 | ||||
| PLX | Protalix Biotherapeutics | 0.86 | ||||
| MCRB | Seres Therapeutics | 1.32 | ||||
| ANTX | AN2 Therapeutics | 1.75 | ||||
| AKBA | Akebia Ther | 2.70 | ||||
| ACLX | Arcellx | 3.38 | ||||
| RCUS | Arcus Biosciences | 3.58 | ||||
| INMB | INmune Bio | 3.61 | ||||
| ETNB | 89bio | 3.79 | ||||
| ANEB | Anebulo Pharmaceuticals | 4.31 | ||||
| STOK | Stoke Therapeutics | 5.73 | ||||
| TNXP | Tonix Pharmaceuticals | 6.11 | ||||
| SANA | Sana Biotechnology | 6.90 | ||||
| CDTX | Cidara Therapeutics | 7.43 | ||||
| VXRT | Vaxart | 7.84 | ||||
| FATE | Fate Therapeutics | 8.04 | ||||
| MDGL | Madrigal Pharmaceuticals | 8.15 | ||||
| PLRX | Pliant Therapeutics | 59.88 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |